Summit Therapeutics INC 10-Q quarterly reports

Summit Therapeutics reports on progress in ivonescimab clinical trials and financial performance for Q2 2026, highlighting ongoing development and need for future financing.

Summit Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development of ivonescimab and substantial doubt regarding its ability to continue as a going concern.

Summit Therapeutics reported a significantly wider net loss in Q3 2025, driven by increased R&D and administrative expenses, despite positive clinical trial updates for ivonescimab.

Summit Therapeutics reported a significantly increased net loss in Q2 2025, driven by substantial R&D and G&A expenses, despite positive Phase III ivonescimab data and recent capital raises.

Summit Therapeutics' Q1 2025 results reflect increased investment in the clinical development of ivonescimab, a novel bispecific antibody for oncology.

Summit Therapeutics reported its Q3 2024 financial results and provided updates on the clinical development of its lead candidate, ivonescimab, including the completion of enrollment in the HARMONi trial.

Summit Therapeutics' Q2 2024 report highlights increased R&D spending, a net loss, and the expansion of its ivonescimab license territory.

Summit Therapeutics reported a net loss of $43.5 million for Q1 2024, with a significant increase in research and development expenses related to its lead candidate, ivonescimab, while also expressing substantial doubt about its ability to continue as a going concern.